Cornercap Investment Counsel Inc. Cuts Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Cornercap Investment Counsel Inc. lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 40.4% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,300 shares of the company’s stock after selling 3,594 shares during the period. Cornercap Investment Counsel Inc.’s holdings in Neurocrine Biosciences were worth $611,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC acquired a new position in shares of Neurocrine Biosciences during the second quarter valued at approximately $28,000. Innealta Capital LLC acquired a new position in Neurocrine Biosciences in the 2nd quarter valued at $30,000. New Covenant Trust Company N.A. purchased a new position in Neurocrine Biosciences in the 1st quarter valued at $32,000. EdgeRock Capital LLC purchased a new stake in shares of Neurocrine Biosciences during the second quarter worth $35,000. Finally, Plato Investment Management Ltd purchased a new stake in shares of Neurocrine Biosciences during the first quarter worth $41,000. 92.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on NBIX shares. StockNews.com lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. HC Wainwright reaffirmed a “buy” rating and issued a $190.00 target price on shares of Neurocrine Biosciences in a research report on Friday, November 1st. Barclays cut their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a research note on Monday, September 9th. Finally, BMO Capital Markets decreased their target price on Neurocrine Biosciences from $128.00 to $114.00 and set a “market perform” rating for the company in a report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

Neurocrine Biosciences Stock Down 4.4 %

Shares of NASDAQ NBIX opened at $117.44 on Friday. The business has a 50-day moving average price of $118.56 and a 200 day moving average price of $132.81. The stock has a market cap of $11.89 billion, a PE ratio of 31.49 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52-week low of $107.84 and a 52-week high of $157.98.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.